Refine by
Human Disease Articles & Analysis
108 news found
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced release of its new line of Human Hybrid IgM Control Monoclonal Antibodies for research applications, covering a range of diseases such as CMV, HSV, MeV, MuV, RuV, and VZV.Characteristic disease state sera are serum samples derived from ...
Idiopathic pulmonary fibrosis (IPF) is a devastating disease characterized by progressive scarring of the lungs, which severely impairs lung function over time. Developing effective treatments for IPF has been a challenge for the medical community, as the mechanisms driving this disease are complex and not fully understood. To accelerate drug discovery, ...
These models have been specifically designed to enable research on different types of diabetes including type 1, type 2, and gestational diabetes, providing valuable insights into disease mechanisms and potential treatment options. Diabetes mellitus is a chronic, systemic, metabolic disease caused by the long-term combination of genetic factors and ...
Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) are major global health threats. Their interaction worsens disease severity, as HIV reduces CD4+ T cells, making individuals more vulnerable to TB. ...
Moreover, this methodology will also help bridge the gap between animal models and human diseases, leading to enhanced translational research. One of the lead researchers behind animal behavioral research shared the significance of this breakthrough: “Understanding the cognitive manifestations of diseases is crucial for developing ...
HLA regions are associated with the greatest number of human diseases in the human genome, and HLA typing is particularly important for assessing immune compatibility between organ donor and recipient pairs. There are more than 100 kinds of diseases related to HLA, involving autoimmune diseases, immunodeficiency ...
Cell separation workflows are foundational to medical research, and the Company’s CytoR1 Platform is revolutionary in its ability to discern and rapidly recover populations of live cells by exploiting biophysical differences, thereby providing more accurate insight into human disease. The Company believes its technologies will become widely adopted for use ...
TMAs, such as aHUS, are rare diseases primarily affecting the kidney. They are hard to diagnose using traditional methods as they present as a number of nonspecific symptoms, such as severe hypertension, acute kidney injury/failure in the context of mechanical anemia and thrombocytopenia. ...
It is well accepted that vaccination is one of the most effective ways to prevent diseases. A vaccine helps the body’s immune system to recognize and fight pathogens like bacteria or viruses, which then keeps humans safe from the diseases they cause. Vaccines protect against a range of diseases, including ...
ByNuvonis
The Analytical Glycoimmunology Group at Macquarie University conducts fundamental biomedical-focused research exploring the importance of sugary-proteins (glycoproteins) in human health and disease. With a strong focus on unpicking the glycobiology of the innate immune system, the group seeks to advance molecular and cellular understanding of the role of ...
AskBio has been driving Bayer’s pipeline of investigational novel gene therapies that are developed across a range of neuromuscular, central nervous system, cardiovascular and metabolic disease indications. Most advanced in the clinic are investigational treatments for Parkinson’s disease, Pompe disease and congestive heart failure. ...
ByBayer AG
About HemoShear Therapeutics HemoShear Therapeutics, Inc. is a privately held clinical stage company developing treatments for rare diseases with significant unmet patient need. HemoShear’s drug discovery platform, REVEAL-Tx™, enables the Company’s scientists to create best-in-class, biologically relevant human disease models ...
About HemoShear Therapeutics HemoShear Therapeutics, Inc. is a privately held clinical stage company developing treatments for rare diseases with significant unmet patient need. HemoShear’s drug discovery platform, REVEAL-Tx™, enables the Company’s scientists to create best-in-class, biologically relevant human disease models ...
NEW YORK, Oct. 12, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today provided an update on the status of multiple clinical trials now underway to assess the safety and efficacy of TPOXX to treat monkeypox. In recent weeks, randomized, placebo-controlled clinical trials were initiated in ...
(RHI), a private, preclinical stage gene therapy company focusing on diseases affecting human hearing to develop a novel gene therapy for DFNB8 genetic hearing loss that includes low-dose recombinant adeno-associated virus (rAAV) gene therapy delivery of a therapeutic TMPRSS3 (transmembrane protease, serine 3) gene by local administration directly to the inner ...
Clinical research activities link OS to several chronic human diseases, such as cardiovascular diseases, cognitive decline, diabetes, premature aging and frailty. ...
Mitochondrial gene expression study is helpful in revealing human diseases associated with mitochondria. On the one hand, it can offer clues for the research of mitochondrial gene function, uncovering the molecular mechanism for the occurrence and development of mitochondrial diseases. ...
The milestone acknowledges development of a human tissue-based model of an undisclosed rare liver disease using the company’s REVEAL-Tx™ platform. REVEAL-Tx™ combines physiological and computational models of disease to identify novel treatment approaches and select drug candidates in a human-relevant ...
With its ready-to-use models and assays for cardiac diseases, customers can accurately analyze the relationship between diseases and mitochondria. Mitochondrial DNA (mtDNA) plays an important role in the pathogenesis of the cardiovascular disease (CVD), especially in heart failure and ischemic heart disease. ...
("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced that the Company has signed an agreement with Greenstone Biosciences Inc. in Palo Alto, CA for the development of a human induced pluripotent stem cell (iPSC) ...